KR20190006029A - Vl 도메인을 함유하는 중쇄를 발현하는 사람화된 설치류 - Google Patents

Vl 도메인을 함유하는 중쇄를 발현하는 사람화된 설치류 Download PDF

Info

Publication number
KR20190006029A
KR20190006029A KR1020187037872A KR20187037872A KR20190006029A KR 20190006029 A KR20190006029 A KR 20190006029A KR 1020187037872 A KR1020187037872 A KR 1020187037872A KR 20187037872 A KR20187037872 A KR 20187037872A KR 20190006029 A KR20190006029 A KR 20190006029A
Authority
KR
South Korea
Prior art keywords
human
mouse
gene
adam6
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187037872A
Other languages
English (en)
Korean (ko)
Inventor
린 맥도날드
케이건 규레르
캐롤리나 에이. 메거
션 스티븐스
앤드류 제이. 머피
Original Assignee
리제너론 파마슈티칼스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리제너론 파마슈티칼스 인코포레이티드 filed Critical 리제너론 파마슈티칼스 인코포레이티드
Publication of KR20190006029A publication Critical patent/KR20190006029A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24046—Adamalysin (3.4.24.46)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Housing For Livestock And Birds (AREA)
  • Central Heating Systems (AREA)
KR1020187037872A 2012-02-01 2013-02-01 Vl 도메인을 함유하는 중쇄를 발현하는 사람화된 설치류 Ceased KR20190006029A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261593463P 2012-02-01 2012-02-01
US61/593,463 2012-02-01
US201261677538P 2012-07-31 2012-07-31
US61/677,538 2012-07-31
PCT/US2013/024295 WO2013116609A1 (en) 2012-02-01 2013-02-01 Humanized rodents that express heavy chains containing vl domains

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147024417A Division KR20140123983A (ko) 2012-02-01 2013-02-01 Vl 도메인을 함유하는 중쇄를 발현하는 사람화된 설치류

Publications (1)

Publication Number Publication Date
KR20190006029A true KR20190006029A (ko) 2019-01-16

Family

ID=47714588

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187037872A Ceased KR20190006029A (ko) 2012-02-01 2013-02-01 Vl 도메인을 함유하는 중쇄를 발현하는 사람화된 설치류
KR1020147024417A Ceased KR20140123983A (ko) 2012-02-01 2013-02-01 Vl 도메인을 함유하는 중쇄를 발현하는 사람화된 설치류

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020147024417A Ceased KR20140123983A (ko) 2012-02-01 2013-02-01 Vl 도메인을 함유하는 중쇄를 발현하는 사람화된 설치류

Country Status (26)

Country Link
US (3) US20130212719A1 (enExample)
EP (3) EP3912465A1 (enExample)
JP (6) JP2015505477A (enExample)
KR (2) KR20190006029A (enExample)
CN (2) CN106117364B (enExample)
AU (3) AU2013204758B2 (enExample)
BR (1) BR112014018843B1 (enExample)
CA (1) CA2863175A1 (enExample)
CY (2) CY1122419T1 (enExample)
DK (2) DK3597038T3 (enExample)
ES (2) ES2870703T3 (enExample)
HR (2) HRP20192218T1 (enExample)
HU (2) HUE055610T2 (enExample)
IL (3) IL233827A0 (enExample)
LT (2) LT2809150T (enExample)
ME (1) ME03611B (enExample)
MX (2) MX373286B (enExample)
NZ (5) NZ734504A (enExample)
PL (2) PL2809150T3 (enExample)
PT (2) PT2809150T (enExample)
RS (2) RS59699B1 (enExample)
RU (2) RU2664185C2 (enExample)
SG (3) SG11201404477YA (enExample)
SI (2) SI2809150T1 (enExample)
SM (2) SMT202100401T1 (enExample)
WO (1) WO2013116609A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110020860A (ko) * 2008-05-23 2011-03-03 알리바 바이오파마수티컬스, 아이엔씨. 유전자 삽입동물에서 단일 ｖｌ 도메인 항체를 생산하는 방법
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CA2807282A1 (en) * 2010-08-02 2012-02-09 Regeneron Pharamaceuticals, Inc. Mice that make binding proteins comprising vl domains
FI3865581T3 (fi) 2011-08-05 2024-11-02 Regeneron Pharma Humanisoituja universaaleja kevytketjun hiiriä
CN103945689B (zh) 2011-09-19 2016-10-19 科马布有限公司 免疫球蛋白基因多样性的操纵及多抗体治疗剂
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9706759B2 (en) 2011-12-20 2017-07-18 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
EP3912465A1 (en) * 2012-02-01 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
KR102266274B1 (ko) 2012-06-12 2021-06-17 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
TR201810255T4 (tr) 2013-02-20 2018-08-27 Regeneron Pharma Modifiye edilmiş immunoglobulin ağır zincir sekanslarına sahip olan insan olmayan hayvanlar.
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
AU2014330922A1 (en) 2013-10-01 2016-03-03 Kymab Limited Animal models and therapeutic molecules
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
CA3124228C (en) 2014-03-21 2024-05-14 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
WO2016149678A1 (en) * 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
US20180094243A1 (en) * 2015-04-03 2018-04-05 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
CN118185874A (zh) * 2016-04-04 2024-06-14 苏黎世联邦理工学院 一种重组哺乳动物b细胞
EP4368637A3 (en) 2016-05-20 2024-07-10 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
US11089767B2 (en) * 2017-03-30 2021-08-17 Utah State University Transgenic silkworms expressing spider silk
EP3720279B1 (en) * 2017-12-05 2022-09-21 Regeneron Pharmaceuticals, Inc. Mice having an engineered immunoglobulin lambda light chain and uses thereof
SMT202500038T1 (it) * 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
IL318469A (en) * 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
KR20230066386A (ko) 2020-09-11 2023-05-15 리제너론 파마슈티칼스 인코포레이티드 항원 특이적 항체의 확인 및 제조
CA3199879A1 (en) 2020-12-16 2022-06-23 Regeneron Pharmaceuticals, Inc. Mice expressing humanized fc alpha receptors
CN114645042A (zh) * 2020-12-18 2022-06-21 中国食品药品检定研究院 一种构建具有表达荧光素酶和红色荧光蛋白的重组巨噬细胞的转基因小鼠的方法
CN114196626A (zh) * 2022-02-16 2022-03-18 北京国卫生物科技有限公司 脐带间充质干细胞及其分离培养扩增方法
AU2024329875A1 (en) * 2024-01-02 2025-07-17 Gempharmatech Co., Ltd Animal model generating humanized antibody and construction method thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
CA2422155A1 (en) * 2000-08-03 2002-02-14 Wim Van Schooten Production of humanized antibodies in transgenic animals
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN101016543A (zh) * 2000-11-17 2007-08-15 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的多核苷酸的方法
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
ATE501167T1 (de) 2001-12-21 2011-03-15 Thrombogenics Nv Zusammensetzungen für die in vitro herleitung und kultur embryonaler stammzellinien mit keimbahnübertragungsfähigkeit und für die kultur adulter stammzellen
WO2003081993A2 (en) * 2002-03-22 2003-10-09 Origen Therapeutics Transgenic aves producing human polyclonal antibodies
CN1852925A (zh) * 2003-07-15 2006-10-25 人类多克隆治疗公司 人源化免疫球蛋白基因座
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
US20080184380A1 (en) * 2004-10-22 2008-07-31 Therapeutic Human Polyclonals Inc. Suppression of Endogenous Immunoglobulin Expression in Non-Human Transgenic Animals
AU2007235496B2 (en) * 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
WO2008027986A2 (en) * 2006-09-01 2008-03-06 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
CN101970491A (zh) * 2007-08-30 2011-02-09 沃尔特及伊莱萨霍尔医学研究院 树突状细胞标记物及其用途
RU2526512C2 (ru) * 2007-09-26 2014-08-20 Чугаи Сейяку Кабусики Кайся Модифицированная константная область антитела
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
KR20110020860A (ko) * 2008-05-23 2011-03-03 알리바 바이오파마수티컬스, 아이엔씨. 유전자 삽입동물에서 단일 ｖｌ 도메인 항체를 생산하는 방법
PL3456190T3 (pl) * 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
KR20110058861A (ko) * 2008-08-29 2011-06-01 심포젠 에이/에스 조류 유래 항체의 클로닝 방법
CA2750520C (en) * 2009-02-04 2017-12-05 Molecular Innovations Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin, and antibodies used therein
EP2564695B1 (en) * 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
CA2802591A1 (en) * 2010-06-17 2011-12-22 Kymab Limited Animal models and therapeutic molecules
CA2807282A1 (en) * 2010-08-02 2012-02-09 Regeneron Pharamaceuticals, Inc. Mice that make binding proteins comprising vl domains
HUE047687T2 (hu) * 2011-02-25 2020-05-28 Regeneron Pharma ADAM6 egér
FI3865581T3 (fi) * 2011-08-05 2024-11-02 Regeneron Pharma Humanisoituja universaaleja kevytketjun hiiriä
US9706759B2 (en) * 2011-12-20 2017-07-18 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
EP3912465A1 (en) * 2012-02-01 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized rodents that express heavy chains containing vl domains
KR102266274B1 (ko) * 2012-06-12 2021-06-17 리제너론 파마슈티칼스 인코포레이티드 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물
CN109996441B (zh) * 2016-11-04 2022-02-08 瑞泽恩制药公司 具有经工程化的免疫球蛋白λ轻链基因座的非人类动物

Also Published As

Publication number Publication date
DK3597038T3 (da) 2021-06-28
AU2015246154A1 (en) 2015-11-12
LT2809150T (lt) 2019-10-25
IL268675A (en) 2019-10-31
PL3597038T3 (pl) 2021-11-08
PL2809150T3 (pl) 2020-04-30
PT2809150T (pt) 2019-12-09
PT3597038T (pt) 2021-05-10
KR20140123983A (ko) 2014-10-23
BR112014018843B1 (pt) 2024-02-20
CN104202971B (zh) 2016-07-06
IL261280A (en) 2018-10-31
JP2018075041A (ja) 2018-05-17
HUE055610T2 (hu) 2021-12-28
MX2019002517A (es) 2019-06-17
CN106117364A (zh) 2016-11-16
IL261280B (en) 2019-08-29
EP3912465A1 (en) 2021-11-24
ME03611B (me) 2020-07-20
SI3597038T1 (sl) 2021-07-30
AU2017251848A1 (en) 2017-11-16
BR112014018843A8 (pt) 2019-01-29
CY1124361T1 (el) 2022-07-22
EP3597038B1 (en) 2021-04-21
JP2019170395A (ja) 2019-10-10
RU2770016C2 (ru) 2022-04-14
NZ810648A (en) 2025-11-28
US20210368751A1 (en) 2021-12-02
HK1202771A1 (en) 2015-10-09
ES2870703T3 (es) 2021-10-27
LT3597038T (lt) 2021-05-25
WO2013116609A1 (en) 2013-08-08
IL233827A0 (en) 2014-09-30
IL268675B (en) 2020-11-30
SG11201404477YA (en) 2014-08-28
EP2809150A1 (en) 2014-12-10
JP2021137030A (ja) 2021-09-16
MX2020003491A (es) 2022-10-25
SMT201900685T1 (it) 2020-01-14
SI2809150T1 (sl) 2019-11-29
JP2023014242A (ja) 2023-01-26
JP7525579B2 (ja) 2024-07-30
CA2863175A1 (en) 2013-08-08
US20130212719A1 (en) 2013-08-15
AU2015246154B2 (en) 2017-11-23
RU2018122695A3 (enExample) 2021-10-06
HRP20210987T1 (hr) 2021-09-17
NZ719228A (en) 2022-08-26
CY1122419T1 (el) 2021-01-27
DK2809150T3 (da) 2019-12-09
HUE046744T2 (hu) 2020-03-30
NZ734504A (en) 2022-10-28
SG10201606256TA (en) 2016-09-29
NZ627977A (en) 2016-06-24
SG10201913428QA (en) 2020-03-30
RU2664185C2 (ru) 2018-08-15
CN106117364B (zh) 2021-08-31
JP2015505477A (ja) 2015-02-23
JP7187615B2 (ja) 2022-12-12
JP2023168590A (ja) 2023-11-24
EP2809150B1 (en) 2019-09-18
AU2013204758B2 (en) 2015-07-23
BR112014018843A2 (pt) 2017-07-04
HRP20192218T1 (hr) 2020-03-06
US20170094955A1 (en) 2017-04-06
MX373286B (es) 2020-05-20
SMT202100401T1 (it) 2021-09-14
ES2753774T3 (es) 2020-04-14
RS62023B1 (sr) 2021-07-30
RS59699B1 (sr) 2020-01-31
CN104202971A (zh) 2014-12-10
EP3597038A1 (en) 2020-01-22
AU2013204758A1 (en) 2013-08-15
RU2014133653A (ru) 2016-03-20
AU2017251848B2 (en) 2020-02-20
RU2018122695A (ru) 2019-03-06
JP6698718B2 (ja) 2020-05-27
NZ793447A (en) 2024-05-31
JP6942757B2 (ja) 2021-09-29

Similar Documents

Publication Publication Date Title
RU2770016C2 (ru) Гуманизированные грызуны, которые экспрессируют тяжелые цепи, содержащие домены vl
KR102186822B1 (ko) 인간화 경쇄 마우스
ES2640139T3 (es) Ratones de cadena pesada de inmunoglobulina restringida
CN107602696B (zh) 人源化的通用轻链小鼠
AU2016202488C1 (en) Common light chain mouse
CN105861548B (zh) Adam6小鼠
RU2724736C2 (ru) МЫШИ, ЭКСПРЕССИРУЮЩИЕ ЛЕГКУЮ ЦЕПЬ С ВАРИАБЕЛЬНОЙ ОБЛАСТЬЮ λ ЧЕЛОВЕКА И КОНСТАНТНОЙ ОБЛАСТЬЮ МЫШИ
CN108611369B (zh) 表达限制的免疫球蛋白轻链库的小鼠
CN107361011B (zh) 制备表达ph敏感性免疫球蛋白序列的非人动物的方法
KR20110020860A (ko) 유전자 삽입동물에서 단일 ｖｌ 도메인 항체를 생산하는 방법
CN113874511A (zh) 具有从κ基因座表达的有限λ轻链谱系的非人类动物和其用途
RU2787781C2 (ru) Мыши с гуманизированной универсальной легкой цепью
HK40020364B (en) Humanized rodents that express heavy chains containing vl domains
HK40020364A (en) Humanized rodents that express heavy chains containing vl domains

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20181227

Application number text: 1020147024417

Filing date: 20140829

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20190125

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190718

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200130

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190718

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I